KYMR
Kymera Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$108.07
+3.14%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 272.66x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 5.95x
- Price / sales
- 85.59x
- Price / cash flow
- -37.95x
Enterprise value
- Enterprise value
- $8.4B
- EV / sales
- 79.79x
- EV / EBITDA
- -28.75x
- EV / EBIT
- -23.92x
- Market cap
- $9.0B
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026